Odaia, an AI-powered startup, recently raised $25 million from investors with the help of a 14-slide presentation. Founded in 2018, Odaia offers pharmaceutical sales and marketing teams a platform that offers insights and data analysis, helping them better target drugs to healthcare providers and simplify the expensive and labor-intensive process.
Philip Poulidis, the CEO and cofounder of Odaia, said that not many advancements have been applied to the commercialization process of drugs, which is usually the bottleneck in the healthcare system. As of February, Odaia had managed 13 therapeutic products on its platform, and its clients included some of the largest pharmaceutical companies in the world.
The Series B round was led by Threshold Ventures and Monograph Capital, while other investors such as Wittington Ventures and Flint Capital also participated. The startup is consideralely working on changing the way pharmaceutical marketing is done, and it hopes to better-target drugs to healthcare providers and make the process easier for everyone involved.
Philip Poulidis is a highly experienced tech entrepreneur and a cofounder of Odaia. He’s been instrumental in the company’s success, leading the Series B round and providing key insights into the commercialization process of drugs. He has a passion for driving change in the industry and is working hard to revolutionize the pharmaceutical marketing industry.
Odaia has revolutionized the pharmaceutical marketing industry, leveraging AI to make a real impact in the commercialization process. This round of funding will ensure that Odaia can scale its platform worldwide, offering an efficient and cost-effective way for pharmaceutical companies to better target drugs to healthcare providers. The company looks forward to scaling its product and continuing to revolutionize the industry.
